Context Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
CNTX$0.19-6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balance at January 1, 2023 | 15,966,053 | $15,966 | $78,832,779 | $(44,090,379) | $34,758,366 | ||||
| Share-based compensation expense | — | — | 1,076,865 | — | 1,076,865 | ||||
| Net loss | — | — | — | (23,964,211) | (23,964,211) | ||||
| Balance at December 31, 2023 | 15,966,053 | $15,966 | $79,909,644 | $(68,054,590) | $11,871,020 | ||||
| Share-based compensation expense | — | — | 841,867 | — | 841,867 | ||||
| Sale of common stock and prefunded warrants in private placement, net of offering costs of $5,234,020 | 59,032,259 | 59,032 | 94,699,715 | — | 94,758,747 | ||||
| Sale of common stock from ATM facility, net of offering costs of $480,268 | 14,705,882 | 14,706 | 14,505,026 | — | 14,519,732 | ||||
| Net loss | — | — | — | (26,725,104) | (26,725,104) | ||||
| Balance at December 31, 2024 | 89,704,194 | $89,704 | $189,956,252 | $(94,779,694) | $95,266,262 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.